Shots:
Ascletis Pharma reported that the first participants have been dosed in a US 13-week P-II study of ASC30, an oral small-molecule GLP-1 receptor agonist, for the treatment of type 2 diabetes mellitus, with topline data expected in Q3’26
The study will enroll ~100 pts and evaluate ASC30’s effects on HbA1c as a 1EP, and…
